Drugs / AFX3772
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05412030 | Jun 2022 → Sep 2025 | streptococcal pneumonia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFX3772 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05412030 ↗ |
| Modality | Vaccine | “AFX3772 Vaccine” NCT05412030 ↗ |
| Route | Intramuscular | “AFX3772 administered intramuscularly.” NCT05412030 ↗ |